InsiderTrades.com logo
China Stockpiling Gold “Like No Tomorrow”
From True Gold Republic   |   Ad
For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… .
Click here now to get your free 'De-Dollarization' Guide.

CADL Insider Trading

Insider Ownership Percentage: 41.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $559,636.01

Candel Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Candel Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Candel Therapeutics Share Price & Price History

Current Price: $7.76
Price Change: ▲ Price Increase of +0.73 (10.39%)
As of 09/18/2024 01:00 AM ET

This chart shows the closing price history over time for CADL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
War on Elon Escalates…
From Porter & Company   |   Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.

Candel Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/17/2024Charles SchochInsiderSell9,884$6.47$63,949.4862,520View SEC Filing Icon  
7/17/2024Paul Peter TakCEOSell22,528$6.47$145,756.16330,735View SEC Filing Icon  
7/17/2024Seshu TyagarajanCTOSell14,851$6.47$96,085.97146,049View SEC Filing Icon  
7/11/2024Charles SchochInsiderSell8,897$5.97$53,115.0972,404View SEC Filing Icon  
7/11/2024Paul Peter TakCEOSell20,293$5.97$121,149.21353,263View SEC Filing Icon  
7/11/2024Seshu TyagarajanCTOSell13,330$5.97$79,580.10160,900View SEC Filing Icon  
12/8/2022Francesca BaroneInsiderBuy1,238$1.61$1,993.182,738View SEC Filing Icon  
12/8/2022Jason AmelloCFOBuy3,100$1.69$5,239.003,100View SEC Filing Icon  
12/8/2022Joseph C PapaDirectorBuy3,014$1.70$5,123.803,014View SEC Filing Icon  
12/8/2022Paul Peter TakCEOBuy3,050$1.70$5,185.0028,050View SEC Filing Icon  
12/8/2022Seshu TyagarajanCTOBuy3,000$1.69$5,070.003,000View SEC Filing Icon  
See Full Table
Trump’s weapon lurks in abandoned America
From Porter & Company   |   Ad
Unemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…
Go here now to watch my new documentary

SEC Filings (Institutional Ownership Changes) for Candel Therapeutics (NASDAQ:CADL)

13.93% of Candel Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CADL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Candel Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
9/16/2024Point72 DIFC Ltd4,927$31K0.0%N/A0.017%Search for SEC Filing on Google Icon
9/16/2024Cubist Systematic Strategies LLC26,121$0.16M0.0%N/A0.088%Search for SEC Filing on Google Icon
8/14/2024Cubist Systematic Strategies LLC26,121$0.16M0.0%N/A0.088%Search for SEC Filing on Google Icon
8/14/2024Point72 DIFC Ltd4,927$31K0.0%N/A0.017%Search for SEC Filing on Google Icon
8/13/2024Sands Capital Ventures LLC405,837$2.52M0.8%-50.0%1.364%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC20,600$0.13M0.0%-63.8%0.069%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers22,985$0.14M0.0%N/A0.077%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp54,449$0.34M0.0%N/A0.183%Search for SEC Filing on Google Icon
1/29/2024Baystate Wealth Management LLC76,910$0.11M0.0%-21.0%0.266%Search for SEC Filing on Google Icon
5/10/2023Resources Investment Advisors LLC.25,428$34K0.0%N/A0.088%Search for SEC Filing on Google Icon
4/25/2023Baystate Wealth Management LLC105,854$0.14M0.0%N/A0.366%Search for SEC Filing on Google Icon
11/14/2022Point72 Asset Management L.P.403,131$1.27M0.0%-45.7%1.395%Search for SEC Filing on Google Icon
5/6/2022Empirical Asset Management LLC12,000$61K0.1%N/A0.042%Search for SEC Filing on Google Icon
4/26/2022Kestra Advisory Services LLC12,500$64K0.0%N/A0.044%Search for SEC Filing on Google Icon
2/15/2022Northpond Ventures LLC1,935,215$15.13M5.3%N/A6.745%Search for SEC Filing on Google Icon
2/15/2022683 Capital Management LLC40,929$0.32M0.0%N/A0.143%Search for SEC Filing on Google Icon
11/15/2021Caas Capital Management LP50,000$0.54M0.0%N/A0.174%Search for SEC Filing on Google Icon
11/15/2021Franklin Resources Inc.1,125,000$12.20M0.0%N/A3.921%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.22,326$0.24M0.0%N/A0.078%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Candel Therapeutics logo
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Read More on Candel Therapeutics

Today's Range

Now: $7.76
Low: $6.91
High: $7.86

50 Day Range

MA: $6.06
Low: $5.02
High: $7.29

52 Week Range

Now: $7.76
Low: $0.66
High: $14.30

Volume

397,619 shs

Average Volume

2,173,994 shs

Market Capitalization

$230.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Candel Therapeutics?

Candel Therapeutics' top insider shareholders include:
  1. Paul Peter Tak (CEO)
  2. Seshu Tyagarajan (CTO)
  3. Charles Schoch (Insider)
  4. Jason Amello (CFO)
  5. Joseph C Papa (Director)
  6. Francesca Barone (Insider)
Learn More about top insider investors at Candel Therapeutics.

Who are the major institutional investors of Candel Therapeutics?

Candel Therapeutics' top institutional shareholders include:
  1. Sands Capital Ventures LLC — 1.36%
  2. Bank of New York Mellon Corp — 0.18%
  3. Cubist Systematic Strategies LLC — 0.09%
  4. Cubist Systematic Strategies LLC — 0.09%
  5. Rhumbline Advisers — 0.08%
  6. Renaissance Technologies LLC — 0.07%
Learn More about top institutional investors of Candel Therapeutics stock.

Which major investors are selling Candel Therapeutics stock?

In the previous quarter, CADL stock was sold by these institutional investors:
  1. Sands Capital Ventures LLC
  2. Renaissance Technologies LLC
During the last year, company insiders that have sold Candel Therapeutics company stock include:
  1. Paul Peter Tak (CEO)
  2. Seshu Tyagarajan (CTO)
  3. Charles Schoch (Insider)
Learn More investors selling Candel Therapeutics stock.

Which major investors are buying Candel Therapeutics stock?

Within the last quarter, CADL stock was purchased by institutional investors including:
  1. Bank of New York Mellon Corp
  2. Cubist Systematic Strategies LLC
  3. Cubist Systematic Strategies LLC
  4. Rhumbline Advisers
  5. Point72 DIFC Ltd
  6. Point72 DIFC Ltd
During the last year, these company insiders have bought Candel Therapeutics stock:
  1. Paul Peter Tak (CEO)
  2. Seshu Tyagarajan (CTO)
  3. Charles Schoch (Insider)
  4. Jason Amello (CFO)
  5. Joseph C Papa (Director)
Learn More investors buying Candel Therapeutics stock.
China Stockpiling Gold “Like No Tomorrow”
From True Gold Republic   |   Ad
For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… .
Click here now to get your free 'De-Dollarization' Guide.